Recent Quotes

My Watchlist

Indicators

Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA )

42.60 +0.55 (+1.31%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,228,091
Open	41.66
Bid (Size)	42.47 (1)
Ask (Size)	42.51 (7)
Prev. Close	42.05
Today's Range	40.96 - 45.06
52wk Range	14.20 - 51.61
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 22, 2024

From Vera Therapeutics

Via GlobeNewswire

Performance

YTD	+172.90%	+172.90%
1 Month	-9.42%	-9.42%
3 Month	-4.40%	-4.40%
6 Month	+22.10%	+22.10%
1 Year	+168.77%	+168.77%

More News

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

November 18, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 11, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

November 11, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

November 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 07, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

October 29, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

October 28, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

October 28, 2024

Via Benzinga

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

October 28, 2024

Via Benzinga

Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug

October 28, 2024

Via Investor's Business Daily

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

October 26, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 04, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

October 02, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

October 02, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

September 16, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

September 12, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2024

From Vera Therapeutics

Via GlobeNewswire

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday

September 03, 2024

Via Benzinga

Vera Therapeutics to Participate at September Investor Conferences

August 29, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 09, 2024

From Vera Therapeutics

Via GlobeNewswire

VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024

August 08, 2024

Via InvestorPlace

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2024

From Vera Therapeutics

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.